{"ticker": {"uuid": "9a54a5f7-3445-44e1-a263-af644888772e", "symbol": "ABBV", "name": "AbbVie Inc", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?", "summary": "AbbVie (ABBV) stock has seen an 8.9% year-to-date rise, driven by investor confidence in its post-Humira growth strategy, particularly the success of Skyrizi and Rinvoq. Despite patent expiry challenges for Humira, the company is bolstering its pipeline through acquisitions like ", "url": "https://www.tradingview.com/news/zacks:59e7035af094b:0-should-you-buy-sell-or-hold-abbv-stock-after-its-9-ytd-rise/", "source_name": "TradingView", "published_at": "2026-07-15T15:07:07", "published_display": "15 Jul 2026 15:07", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citigroup Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/citigroup-adjusts-price-target-abbvie-130735000.html", "source_name": "MT Newswires", "published_at": "2026-07-15T13:07:35+00:00", "published_display": "15 Jul 2026 13:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOZ1NpLXM5SldhOGphdFZpS2xhN1l0OHRzRzUwaTBWNVpuNjc1UzlEY2dqVFo1VHJTRzdmOUxTUlpBUjRoS0NVZDJtaW4xUllzOEdEWXJzMHhvVE9ibTg5dkJzMXpvYTlKM05veVBCRmJCU29HYXpiMWhtSWtTVlVxdS1SNEY3aFZTRU9aZXpUTmFoNUQ3ajYwcFgxcw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T13:00:12+00:00", "published_display": "15 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap", "summary": "This article analyzes a \"golden cross\" technical signal for both AbbVie (ABBV) and Baxter International (BAX), evaluating which stock is better suited for an income-focused retirement portfolio. It concludes that AbbVie is a clear winner due to its robust dividend, strong financi", "url": "https://247wallst.com/investing/2026/07/15/abbvie-vs-baxter-one-golden-cross-is-real-one-is-a-trap/", "source_name": "24/7 Wall St.", "published_at": "2026-07-15T11:46:09", "published_display": "15 Jul 2026 11:46", "sentiment": "positive", "sentiment_pct": 75, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Red day on Tuesday for AbbVie stock after losing 1.31%", "summary": "AbbVie stock (ABBV) fell by 1.31% on July 14, 2026, marking its seventh consecutive daily decline and resulting in a 3.76% drop over the last 10 days. Despite negative short-term signals like a sell signal from a pivot top point, the stock has a general buy signal from its long-t", "url": "https://stockinvest.us/stock-news/red-day-on-tuesday-for-abbvie-stock-after-losing-131-2026-07-14", "source_name": "StockInvest.us", "published_at": "2026-07-15T00:53:57", "published_display": "15 Jul 2026 00:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock Looks Fully Priced After A 152% Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNUFR6SVk5WE9KUXBYcmNQMlRzajNDaHZBandORGp3TzYwQmhYTmhOejV0Rks1aU5UdlZrNGZIbWszSzFTMzIzQml4NHR4dzZDVlVXR01qOHdtbE1EM0d4VXNzWnZWX1NIVG1FcURQZGV6eGZmekVySE9Hc3RFUG5NTnJEdXNpeVpYMWdGTnFzTVFlYUVqNjU0clVR?oc=5", "source_name": "Market source", "published_at": "2026-07-14T22:13:53+00:00", "published_display": "14 Jul 2026 22:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Inc. stock outperforms competitors despite losses on the day", "summary": "AbbVie Inc. (ABBV) shares fell by 1.30% to $244.78 on Tuesday, marking its seventh consecutive day of losses, despite a generally favorable trading session for the broader stock market. The S&P 500 Index rose by 0.38% and the Dow Jones Industrial Average increased by 0.02%. The a", "url": "https://www.marketwatch.com/data-news/abbvie-inc-stock-outperforms-competitors-despite-losses-on-the-day-cc846914-4ae478cea493", "source_name": "MarketWatch", "published_at": "2026-07-14T16:31:00", "published_display": "14 Jul 2026 16:31", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?", "summary": "This article analyzes whether AbbVie (ABBV) is a wise investment, comparing its average brokerage recommendation (ABR) with the Zacks Rank. While Wall Street analysts have an optimistic outlook with an ABR of 1.61 (approximating Strong Buy), the Zacks Rank, a proprietary stock ra", "url": "https://ca.finance.yahoo.com/news/abbvie-abbv-buy-wall-street-133004224.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-14T13:37:01", "published_display": "14 Jul 2026 13:37", "sentiment": "negative", "sentiment_pct": 37, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie price seeks a supportive bottom - Forecast today - 14-07-2026", "summary": "AbbVie Inc. (ABBV) experienced a pullback due to bearish signals after reaching overbought territory, but is now seeking a higher low to rebuild positive momentum. Despite recent weakness, the stock remains above its 50-day Simple Moving Average, indicating a bullish outlook for ", "url": "https://www.economies.com/stocks/united-states-analysis/abbvie-price-seeks-a-supportive-bottom---forecast-today---14-07-2026-128427", "source_name": "Economies.com", "published_at": "2026-07-14T12:07:00", "published_display": "14 Jul 2026 12:07", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb", "summary": "Donald Trump's administration has implemented voluntary drug-pricing agreements with major pharmaceutical companies like Pfizer, AbbVie, and Bristol Myers Squibb, aligning drug prices with those in comparable developed countries. While these deals introduce some pricing pressure,", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/motley/3267888/donald-trump-s-drug-pricing-deals-are-reshaping-big-pharma-here-s-what-that-means-for-pfizer-abbvie-and-bristol-myers-squibb/", "source_name": "The Globe and Mail", "published_at": "2026-07-14T09:19:59", "published_display": "14 Jul 2026 09:19", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie pharmaceutical project moves forward in Durham: 'Huge deal'", "summary": "Durham County leaders are considering a $15 million incentive package for AbbVie, a major pharmaceutical company planning a $1.4 billion investment in a new Durham campus. This project highlights the region's growing pharmaceutical industry and the role of local institutions like", "url": "https://abc11.com/post/abbvie-pharmaceutical-project-moves-forward-durham/19500900/", "source_name": "ABC11 News", "published_at": "2026-07-13T21:51:59", "published_display": "13 Jul 2026 21:51", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (NASDAQ: APGE) backs AbbVie\u2019s $135.11\u2011per\u2011share all\u2011cash deal", "summary": "Apogee Therapeutics (NASDAQ: APGE) has agreed to be acquired by AbbVie through a merger, where Apogee shareholders will receive $135.11 in cash per share. This all-cash deal represents a 53% premium to Apogee\u2019s closing price on June 17, 2026, and a 63% premium to its 30-day volum", "url": "https://www.stocktitan.net/sec-filings/APGE/defm14a-apogee-therapeutics-inc-merger-proxy-statement-b1e8bbc2d957.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:15:59", "published_display": "13 Jul 2026 21:15", "sentiment": "positive", "sentiment_pct": 69, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABBV Maintained by UBS -- Price Target Raised to $260", "summary": "UBS analyst Michael Yee maintained a 'Neutral' rating for AbbVie (ABBV) while increasing the price target from $230.00 to $260.00. Despite the positive outlook reflected by the raised price target, GuruFocus indicates ABBV is currently overvalued by 16.4%, with a GF Value\u2122 of $21", "url": "https://www.gurufocus.com/news/8956056/abbv-maintained-by-ubs-price-target-raised-to-260", "source_name": "GuruFocus", "published_at": "2026-07-13T19:38:04", "published_display": "13 Jul 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating", "summary": "BMO Capital has increased its price target for AbbVie (ABBV) from $258 to $300, while maintaining an \"Outperform\" rating on the stock. This adjustment reflects BMO Capital's continued positive outlook on the biopharmaceutical company. The report also notes other recent analyst ac", "url": "https://www.marketscreener.com/news/bmo-capital-adjusts-price-target-on-abbvie-to-300-from-258-maintains-outperform-rating-ce7f5edcd88af326", "source_name": "marketscreener.com", "published_at": "2026-07-13T14:52:58", "published_display": "13 Jul 2026 14:52", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is AbbVie stock climbing today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOdGVjTlJVNGFxVGctWlAxa3lvX29ZT3ZvTmQ2SHg1WklsYzUwejR5TlZIaGliejdyaGF0NHNOMnBaLVY1TWZVY3pLWEpXT20xaDF1ZlZwMlo1cFFSYUI1MVVad1FuQVJZV3BKUGliWHBOX3RFeVpuLVpPTldBbWhLYzZhSjR6RmJvQVh1UjZIbnZBblVnWDYyMDNrSkc?oc=5", "source_name": "Investing.com", "published_at": "2026-07-13T13:35:51+00:00", "published_display": "13 Jul 2026 13:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating", "summary": "UBS has increased its price target for AbbVie (ABBV) shares to $260 from $230, while maintaining a Neutral rating on the stock. This adjustment comes amidst other analyst revisions for AbbVie, with firms like BMO Capital, BofA Securities, and RBC also updating their price targets", "url": "https://www.marketscreener.com/news/ubs-adjusts-price-target-on-abbvie-to-260-from-230-maintains-neutral-rating-ce7f5edcd98ff12d", "source_name": "marketscreener.com", "published_at": "2026-07-13T14:07:05", "published_display": "13 Jul 2026 14:07", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty", "summary": "AbbVie, though relatively young as a standalone company, has maintained its dividend growth inherited from Abbott, positioning itself as a Dividend King. The acquisition of Apogee Therapeutics for $10.9 billion is a strategic move to bolster its drug pipeline, particularly with d", "url": "https://finance.yahoo.com/healthcare/articles/abbvie-already-dividend-king-heres-003500796.html", "source_name": "Market source", "published_at": "2026-07-12T23:06:57", "published_display": "12 Jul 2026 23:06", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie stock holds steady after a new U.S. market backdrop", "summary": "AbbVie Inc. (US00287Y1091) remains a significant U.S. healthcare company, focusing on its diversified drug portfolio with strong exposure to immunology and aesthetics. The stock's stability is attributed to its broad therapeutic franchise, multiple revenue streams, and establishe", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/abbvie-stock-holds-steady-after-a-new-u-s-market-backdrop/69751563", "source_name": "ad-hoc-news.de", "published_at": "2026-07-12T07:24:59", "published_display": "12 Jul 2026 07:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Sco", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPV1JxaU9DM3NydWo0bVBvaDF1QTczSFFWYmpqN0JXLTduZ04xdmxYWTRaeEtHYTdvVkNwSlNNM0JwZHM4a3RFTGI5OXFhajlwUW1IaXpCTXM3X2Nwak9sbjdCQ1lCM2ttZ2l6X3dGa3VvNWJmM0x5Zzllc1F4UWI2MnJJYjVhNUJ1V2k4ZnpFNTVhMzJlVG4tTm5ITTNiWjRKQmh0QTdDQ2lHSDYwOGc2cC1FUDhNaHM?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-11T00:36:20+00:00", "published_display": "11 Jul 2026 00:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABBV News | ABBVIE INC (NYSE:ABBV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE1XdjVhb0wxSW1QVDRGeGVKYkhDbDhycUpxa1JITjVJZjFfWEdOalprT2VxbnBteEpnNEZNcE5BYXM0dFktVkNQTGQyeXRvRy1zU05iSnk5OENxeUk?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:04:00+00:00", "published_display": "11 Jul 2026 00:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPTGRXdGVwTTByVUs5T0UtSXlZMW9oTmd4dlFITi00LTF4ZkkwMi1GSTZXV2RZdU1VRFJnLThHRDgzZ2R5dTZaWERhVmtJaEdXVkZCN1cxREVydmM5WldNMzlYSU16cnlpcjltOFVDdTBkelphM3lyMDFpRlI1eEpZbW5pbmhVYV96Ui0xRnRQUmFqR0pKaDJBUGR2NDM?oc=5", "source_name": "Market source", "published_at": "2026-07-09T21:45:04+00:00", "published_display": "09 Jul 2026 21:45", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Wins EU Approval For Tepkinly, Is The Stock Fully Valued?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T18:55:36+00:00", "published_display": "08 Jul 2026 18:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock Trades At A Discount To Fair Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNeW42T2J1ZVJwelgwYTZWd2Fhcmtxc1RXTGFCQ0QwOEQ0QTN6dWpMTmtzank5TmcweFpWcWQ2VVlYbTdQUUJ6cTJzY25DNGNfa1pZZUtGNnRZTkNMQlpWekZZRW9ZcC1CTHFtRnZTb0ZmWm9GTlE2Qi1sVnpxNGFqdmVKTEUyWm9VMHQ2ak9IZm9IV05DYUY5aWlUbXpMZm1xU3N5RTVMYTVWWUNnYjZjVTNDX3ZSdGpYUmo2bng1aTJ3Ukg0SVNUNnVR0gHPAUFVX3lxTE1Sb0xHMGZ5c1pETkdHTTNFRzhza2ZhUl9nVE9YOUh3cElBcVBoX1IwMVBxOE53NW56Y29FWGkxOElpaHpSQ2pucW1VN1k4d3dQNkc5Mk0zSHJkNVFmSUIxWDF5djBfOHpOYUJtYU9ycXBlT2cwaGFOVFRYYlVmZGdpdlN5NHdFRWxVTTM0cWpXNVJsdFJtOThSVkp2NmNzc1VuWmNqZVpvMjdzVDlLek0wSm1fSlZJWWtXamg4cnFsZkU1LTlWZ0FDdVl0QWV0WQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNbFZuVGhLck5kN2RTbnlyY05IVE1qMTB1cDFNX0JQcm5sUlRkUWRiRjRLaENRSG15OGdkbnY0ZEkxTndVVFEzdUNBUFJPZktCd2pJZk5GTVB2SHZaaHNLbG1oU2YxMm5hRlB6dE1kS2dVTkE5RzFOeXpaZk51RUVVQlV2Wnh1ZmpacFB2WGNfMkI1VnVUUGhnMENZd0cwQWtqMjRKMFJXMEtabl9GSTZJWXljalJ5ektIdmRJcw?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQblhVZzlvSk1rVU1xcDdOOWlmSUlVSFVhOVY4WXNYTjJyX0NNUFM1Z01Wb1JPaTNnWG1IQkRiRmdfLTJnbUJSX2ZQQ3BSaUd3RllENi1GT2JMSU5sNTN2T3hHS1o4ZkVTblFsbVBGVFA2VWJXRVFuSmRHSnplUEJ5VnVfSzhqb0lXTEhzajhET2RQMWd5MXVoN1UzZktmYnEzeGc?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AbbVie (ABBV) Fully Valued After New Rinvoq And Skyrizi Approvals?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Stock Rockets 17% With 5-Day Winning Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQWlNibHR4Y093endvUXE1REJKYjRkM0RSZ1N1QjJZMl9SMllNVEtBQWJmaHpzQktlMHhEOHh1UU5MQ1ppR3BLLUxlZ1lsUjA2ZDZGZVBhdDQyU0YxWHFTYldBZnRCY1NQQmsxUHFQbjZ2Vkk5UzZtdmtNNmlmRXgzbXNSbVdkY1BpSlBjZGFrRzEyeERMT1ZDVlEzWGhqbDk4cXRQSkxWZDVzZVZsMlRz?oc=5", "source_name": "Trefis", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock After 1-Year 41% Rally And Apogee Deal Valuation Check", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOeC16WWxHNnNDakNqX21pTWdHb0ZpUktlejEyRDQyU3RwNGVkSjk1NTA1SUt2QmxTNmtVSUdiS1hxNlVEYnJCUGlvR0UydnpTcGdMSkY1aHBLNDNmOVYySWxKeUotUndkeG5pM3BIUnpHVmpPbXR5bU1GRG9Pdm1KdGNZSlluWjZ4SktFLTBQZ3c?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNMl9fd1RVMWhLQW9KUU5jRzBWU0F2QmNpbEFWVXFGRk9WQ01HYXUyYmNOVEdQVW12WlZ0RnJ6Z2UyUHJYb3lyYU00RHpEVmZNdC01dEdsakhvWHhrZ2lVSkxISVNNZWJBN0hEZW8zblMxWC1UYVR3Ylg1QWwwYlJCSUN3a0tFaEdlcThFSGpUNmJvakNW?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Stock Leads 3 Cash Flow Picks Trading Below Estimated Value", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock Draws Fresh Price Target Split After Apogee Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOTThub0wyWHVFUFV0Xy1Vck8yOWhxQkdSTlI1M09Jdm1KRzM3ZkFVZ0pQV2MyR0FEemxuZTNfaENJaFpaRmpIdDB6czZHWS1XbTdPSG9BclVxUHFRVDV3SlNoTjRfUnhXNFpxeW5NS181bXNpdXhtQjhtR1lqSVh4bkJIMkFIM0JURFRSTElfZjBrUU1rVmd5aDB3?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie to Acquire Apogee Therapeutics in $10 Billion Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOVVZRdFFhZEtER3ZMRHhJZG02MGpYb0V2cVBuWXdXdUx2bllQMTZtRVBqMENycnhYYVpnUTVOM3hpMHBzZTUxXzMydDYtZlFSSEIyN0pDUEE4SWVhUTZNekM2V0dEWnRfWl8welh5Sk1oSDNuMDJQVzEteGNSclJkOXZaaXVudHZL?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPVFVxY01QUEhnc01sTHFMdnpPVndYWjk5Y01BR29tS1NZLXhyT2ZpelFIcDc0Ql9vRnAwM0pfeW5LMFkzYzNhenpEMTk5UzJjX1pFWmZVOG9iX1dmcXNoY2F6NGZBa0l2Y1NtNXBjMllnZjVxZ3hYeWdLNThienFDSWVqZGlKQnR1S0NObE9MaDRGYjJZempWTGJ6NkdScWZ4SkhSVllMenNmSGh0ckI2bERDSExJUTFCM1Z1Z2pIN1RGS0lkSi1sWXF5TXl3UllyaEhBNVAtNmI?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why AbbVie Stock Jumped Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQQmpBaVhzV2Nyd3hmdmRuQVpJUjhnbXpOajdCdlpVZ3p3LXBkVlAza0VTWkhKeW1jSzc2YmpnUUpUVG1ocjduNlZyQ1dyYTdQdTVNT1AzNUlDWHNBV3dXYkN4Ti02RTk5ZTJlN29NWTFwTG15cHk2UDcyZlM3Y1ltWTNJeVliemYwdlg1d1liNzFUZE5sTlRRaFZn?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNNVdQUG5hMEZpMWh2eHIzNkUtZ2VGajJNX2ltcFF1TmRyQUxDckNCMThudHBKNWlTbHRlb28zQko4MFZaVWRnelFQeGdrM2pnN2Nya0hiS1F3NlA3bXVMeVlFYm1URXJIVVcybnhaYjJUZm1YOTd1b2llcHRKc1pYZ1lKeWZvbVFEbEZpZWNQZWJmbjR1RWtyTm5pdw?oc=5", "source_name": "Market source", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock Weighs DCF Upside Against Elevated P/E At US$227.73", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQZmFkN0p6MUh6T3BVZXY4OFB6YVJEeE1lYXl0X3ZBUUxuczI4TFgzWTBkaDB2MkNPaWtheVdwYWl2SVctSzNrbXk5dFgtMjk2UlVGLWl0UmFZQXFXQmdkUUlGdXRKRVRoczJZZUZWR1ZvRVZpNVQyNU91d25GeUxFXzJoYjV3VFQ4WExxVE9jbXhTYWhmcXFpWA?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AbbVie Inc. (ABBV) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPWDJhb3N0MVdzcUtTTDU5YlI0MGZEdEJMZmszU01TYmpNMFJiUE5uRHJEZVVqak1tbUphNDFLb0lPdzJDM1BzSnZzU2tSd2lNRk1LZFBoY3Q5Z3hXT2lJeWo0X1pYd29xeWRsYjBGTlY4em1LTGcyV2xheF9reFh2VkhpbnplcVhQbzBhUldENlUzYmdUQ0E?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOaC02SmUycjdKa0ZLTS02c0pXblZ2d0xtWVNpZDZPdnNNbU1Pc1pOdWZQbWtwcjNsTmVZSzg1UEw3UElXUjNlYlNmUF9zdVA4NHNHNHZ5ZVNkYVFhSUxua0VNVjZndzA5alFkeUhDWUJkaWJlSXp2d3pGMlkxUkg4VzlqRVBQR2poR2pueEo5NA?oc=5", "source_name": "Market source", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock Trades Up, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPbjNSdm0tWjU0bWtUazdaamZFRFZjOXFrekRzQ1BnTnAyQXJkaW4xTE94UU5hWkdqV002LVpSLUJSSlNQd0xzS3B4REppX2psVjlkTVIyeC1vUm5IbTZPalU0MFJUMG5HSG85RzRHZ1ZjOGgxaElLVXU5OTYxVl9KQ3JCNWJ1eHFUMzJ6Y2h1aW1UVnRNbjloMVBtUEtZcm9w?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Invests $1.4 Billion into New Manufacturing Campus in North Carolina", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxONEFDQV9qWDEtcEtUNHlnYXpHQUYyWUJCTHVhWVJwS204LTNkNlJTVGw1cWU5R0d6R0dYcWlmNmJydzlzNTdoRG14bWhMOW9IWUpCQk1XWWxlUnBoX0VvdXk3YmhkTXJMQzRGeVZQdXd2SFVSVGhlTG9yRUNieFhIbFhPSDRGWUFUVlBuLUdyRkFoRzg2bWVRMHB4WjVUdG8?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPa3FhWENLaVV5TFhFX0ZNQmgtSEZncFJBRjlsUURGT0hKX2tpNGZURURWMjdDOUZ1MWJWUlRHeXRjU2NFRWZkc0ZpalRGUElyRHpKeEZGZmxfQkdEOEdUMTZpcHQxRy1QelVoOXBieEVNWDJibHdteHJYbWFjWHUzUlZ0ZVBsdkM2WGczbFFsbDNnbUVnYmNuQlRRZS0zbU1PYTZWZjZ0MVBtSmlXUFlTQzZDU2RhV1ZzZGc?oc=5", "source_name": "TradingView", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Haisco Enters $745 Million Exclusive License Agreement with AbbVie", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxORGtNdlV6OWh2aWRHeTFiWnFFdGp5a3JSNTBvWW43RlFtS2o1UWYwN2g3LXVuRmlCVGstdWU1ZThHVnJPSUE5RkVyTmVPd2sxeW5HMHMzc0lYUndpU1lYbnhMRGtqVkVoeS1tNzhDOUdicV9QZF9obFhfeGJVb0JrMEc4TmJzb2JUR1VYT1V0dk0yZjJPVEE?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxPZmJKQ3l2S2FkYjlsd0xiQWUwX1V5d3R2cEMzblBrVmNTUEdtdWFndkl6UnAyOTVQYW96VGdiQzlaX3dwQ0FjSUNHVE9mSy1kLTlhX29HUmFfcG55ZlRRV2lfcGl2S2l5ZXc0TUZwcmFxRGFHVjJyWW9EMXk4UVFWRUxQMEZybElFTll6NjNsNUxKcUJ6cEE2aTZPYXpMYXhYRm51LTRlRHp2RXIzQjFfSG1Wc3pVcFkyRVZaUjduTjFOWlZ5TmV1Q1VKWUdPREtlbW5sX3c3MkltOWVXRWlHMEdUSnBBTllFRjQ3bFkwSndnc2FiZFlkOHhB?oc=5", "source_name": "StockStory", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharma Manufacturing Roundup: AbbVie Invests $380 Million to Expand API Manufacturing, Bora Pharmaceuticals and GSK Enters Five Year Manufacturing Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOT2NTdUZpUFVNcEFaeUoyV2JnNVNRVVhxS2NkajNVTjJWQk5HOGdhblBsdjhHNXFsbEZucXVkRmdqTTByVUVXdURjcERLSEM2bWJ5aEV4NkRQRlBHYWVBT0loT2VTSkM2MElLbTR2aWNYd2J3TkFlUDVLQkhBLVJ1dGN3Zkp5cWtDWnRqRGlNeUc4ejlhMVoza0JUZlE3VGp0bkc4YTNLei1DVjhkQXYtaTVYeGlHbEF2ZGtMd1ZFWmpWUGtZUE5iSkdTQ2hkeHF5RUlVRl80UU5fOU1KdGFkZVItSXZXaV9YVXFv?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie\u2019s $380M Illinois build to add 300 jobs, boost obesity drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPV3BsWk1QcVJ4Z3BOdnVvenAwdWFFdzBBTnVWZHZyaF9xelR2dzAyMFVlb0w3c2NfMVowZFFpQXczUktPQ1lMNHdvaUNSUWFKb0Y3Umw0RkdXZWVmZkhzZjhDMDYyNmI3S1RsQmFacmVzMEJWcl9aN3hHQUxRbk9KdWJpd2J2ZF9MMkgtVGVaQm1na3V5bmpLTm5YYnh3b2pFSXlnbGMxT295WFBnX3B5bFU2OGxIaHBEZ1BN?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Joins Trump Drug Pricing Effort, Pledges $100B in US R&D Investment", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNZmdzdGFBWHdqeU9OQzB1ZkZwWUczbTN1cS1vTWJWYjZVaHVPY0F3d1V4ZHhGb0dRQ2x0WnFSUUxpWGtISGx3ZmZ4WmpvakZydS1LYTZaeUdzbFZFRHFuMWFtZ1dkemQyTEw4NlFIUG1CWV81bGpfcndlZ3g2OUhMRElZLWRNc1piUVFRWHNLV0ExdU9jWjI5Yl93c3Zfb1U?oc=5", "source_name": "The American Journal of Managed Care\u00ae (AJMC\u00ae)", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?", "summary": "AbbVie (ABBV) stock has seen an 8.9% year-to-date rise, driven by investor confidence in its post-Humira growth strategy, particularly the success of Skyrizi and Rinvoq. Despite patent expiry challenges for Humira, the company is bolstering its pipeline through acquisitions like ", "url": "https://www.tradingview.com/news/zacks:59e7035af094b:0-should-you-buy-sell-or-hold-abbv-stock-after-its-9-ytd-rise/", "source_name": "TradingView", "published_at": "2026-07-15T15:07:07", "published_display": "15 Jul 2026 15:07", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citigroup Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/citigroup-adjusts-price-target-abbvie-130735000.html", "source_name": "MT Newswires", "published_at": "2026-07-15T13:07:35+00:00", "published_display": "15 Jul 2026 13:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOZ1NpLXM5SldhOGphdFZpS2xhN1l0OHRzRzUwaTBWNVpuNjc1UzlEY2dqVFo1VHJTRzdmOUxTUlpBUjRoS0NVZDJtaW4xUllzOEdEWXJzMHhvVE9ibTg5dkJzMXpvYTlKM05veVBCRmJCU29HYXpiMWhtSWtTVlVxdS1SNEY3aFZTRU9aZXpUTmFoNUQ3ajYwcFgxcw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T13:00:12+00:00", "published_display": "15 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap", "summary": "This article analyzes a \"golden cross\" technical signal for both AbbVie (ABBV) and Baxter International (BAX), evaluating which stock is better suited for an income-focused retirement portfolio. It concludes that AbbVie is a clear winner due to its robust dividend, strong financi", "url": "https://247wallst.com/investing/2026/07/15/abbvie-vs-baxter-one-golden-cross-is-real-one-is-a-trap/", "source_name": "24/7 Wall St.", "published_at": "2026-07-15T11:46:09", "published_display": "15 Jul 2026 11:46", "sentiment": "positive", "sentiment_pct": 75, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Red day on Tuesday for AbbVie stock after losing 1.31%", "summary": "AbbVie stock (ABBV) fell by 1.31% on July 14, 2026, marking its seventh consecutive daily decline and resulting in a 3.76% drop over the last 10 days. Despite negative short-term signals like a sell signal from a pivot top point, the stock has a general buy signal from its long-t", "url": "https://stockinvest.us/stock-news/red-day-on-tuesday-for-abbvie-stock-after-losing-131-2026-07-14", "source_name": "StockInvest.us", "published_at": "2026-07-15T00:53:57", "published_display": "15 Jul 2026 00:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock Looks Fully Priced After A 152% Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNUFR6SVk5WE9KUXBYcmNQMlRzajNDaHZBandORGp3TzYwQmhYTmhOejV0Rks1aU5UdlZrNGZIbWszSzFTMzIzQml4NHR4dzZDVlVXR01qOHdtbE1EM0d4VXNzWnZWX1NIVG1FcURQZGV6eGZmekVySE9Hc3RFUG5NTnJEdXNpeVpYMWdGTnFzTVFlYUVqNjU0clVR?oc=5", "source_name": "Market source", "published_at": "2026-07-14T22:13:53+00:00", "published_display": "14 Jul 2026 22:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Inc. stock outperforms competitors despite losses on the day", "summary": "AbbVie Inc. (ABBV) shares fell by 1.30% to $244.78 on Tuesday, marking its seventh consecutive day of losses, despite a generally favorable trading session for the broader stock market. The S&P 500 Index rose by 0.38% and the Dow Jones Industrial Average increased by 0.02%. The a", "url": "https://www.marketwatch.com/data-news/abbvie-inc-stock-outperforms-competitors-despite-losses-on-the-day-cc846914-4ae478cea493", "source_name": "MarketWatch", "published_at": "2026-07-14T16:31:00", "published_display": "14 Jul 2026 16:31", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?", "summary": "This article analyzes whether AbbVie (ABBV) is a wise investment, comparing its average brokerage recommendation (ABR) with the Zacks Rank. While Wall Street analysts have an optimistic outlook with an ABR of 1.61 (approximating Strong Buy), the Zacks Rank, a proprietary stock ra", "url": "https://ca.finance.yahoo.com/news/abbvie-abbv-buy-wall-street-133004224.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-14T13:37:01", "published_display": "14 Jul 2026 13:37", "sentiment": "negative", "sentiment_pct": 37, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie price seeks a supportive bottom - Forecast today - 14-07-2026", "summary": "AbbVie Inc. (ABBV) experienced a pullback due to bearish signals after reaching overbought territory, but is now seeking a higher low to rebuild positive momentum. Despite recent weakness, the stock remains above its 50-day Simple Moving Average, indicating a bullish outlook for ", "url": "https://www.economies.com/stocks/united-states-analysis/abbvie-price-seeks-a-supportive-bottom---forecast-today---14-07-2026-128427", "source_name": "Economies.com", "published_at": "2026-07-14T12:07:00", "published_display": "14 Jul 2026 12:07", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb", "summary": "Donald Trump's administration has implemented voluntary drug-pricing agreements with major pharmaceutical companies like Pfizer, AbbVie, and Bristol Myers Squibb, aligning drug prices with those in comparable developed countries. While these deals introduce some pricing pressure,", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/motley/3267888/donald-trump-s-drug-pricing-deals-are-reshaping-big-pharma-here-s-what-that-means-for-pfizer-abbvie-and-bristol-myers-squibb/", "source_name": "The Globe and Mail", "published_at": "2026-07-14T09:19:59", "published_display": "14 Jul 2026 09:19", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie pharmaceutical project moves forward in Durham: 'Huge deal'", "summary": "Durham County leaders are considering a $15 million incentive package for AbbVie, a major pharmaceutical company planning a $1.4 billion investment in a new Durham campus. This project highlights the region's growing pharmaceutical industry and the role of local institutions like", "url": "https://abc11.com/post/abbvie-pharmaceutical-project-moves-forward-durham/19500900/", "source_name": "ABC11 News", "published_at": "2026-07-13T21:51:59", "published_display": "13 Jul 2026 21:51", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (NASDAQ: APGE) backs AbbVie\u2019s $135.11\u2011per\u2011share all\u2011cash deal", "summary": "Apogee Therapeutics (NASDAQ: APGE) has agreed to be acquired by AbbVie through a merger, where Apogee shareholders will receive $135.11 in cash per share. This all-cash deal represents a 53% premium to Apogee\u2019s closing price on June 17, 2026, and a 63% premium to its 30-day volum", "url": "https://www.stocktitan.net/sec-filings/APGE/defm14a-apogee-therapeutics-inc-merger-proxy-statement-b1e8bbc2d957.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:15:59", "published_display": "13 Jul 2026 21:15", "sentiment": "positive", "sentiment_pct": 69, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABBV Maintained by UBS -- Price Target Raised to $260", "summary": "UBS analyst Michael Yee maintained a 'Neutral' rating for AbbVie (ABBV) while increasing the price target from $230.00 to $260.00. Despite the positive outlook reflected by the raised price target, GuruFocus indicates ABBV is currently overvalued by 16.4%, with a GF Value\u2122 of $21", "url": "https://www.gurufocus.com/news/8956056/abbv-maintained-by-ubs-price-target-raised-to-260", "source_name": "GuruFocus", "published_at": "2026-07-13T19:38:04", "published_display": "13 Jul 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating", "summary": "BMO Capital has increased its price target for AbbVie (ABBV) from $258 to $300, while maintaining an \"Outperform\" rating on the stock. This adjustment reflects BMO Capital's continued positive outlook on the biopharmaceutical company. The report also notes other recent analyst ac", "url": "https://www.marketscreener.com/news/bmo-capital-adjusts-price-target-on-abbvie-to-300-from-258-maintains-outperform-rating-ce7f5edcd88af326", "source_name": "marketscreener.com", "published_at": "2026-07-13T14:52:58", "published_display": "13 Jul 2026 14:52", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is AbbVie stock climbing today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOdGVjTlJVNGFxVGctWlAxa3lvX29ZT3ZvTmQ2SHg1WklsYzUwejR5TlZIaGliejdyaGF0NHNOMnBaLVY1TWZVY3pLWEpXT20xaDF1ZlZwMlo1cFFSYUI1MVVad1FuQVJZV3BKUGliWHBOX3RFeVpuLVpPTldBbWhLYzZhSjR6RmJvQVh1UjZIbnZBblVnWDYyMDNrSkc?oc=5", "source_name": "Investing.com", "published_at": "2026-07-13T13:35:51+00:00", "published_display": "13 Jul 2026 13:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating", "summary": "UBS has increased its price target for AbbVie (ABBV) shares to $260 from $230, while maintaining a Neutral rating on the stock. This adjustment comes amidst other analyst revisions for AbbVie, with firms like BMO Capital, BofA Securities, and RBC also updating their price targets", "url": "https://www.marketscreener.com/news/ubs-adjusts-price-target-on-abbvie-to-260-from-230-maintains-neutral-rating-ce7f5edcd98ff12d", "source_name": "marketscreener.com", "published_at": "2026-07-13T14:07:05", "published_display": "13 Jul 2026 14:07", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty", "summary": "AbbVie, though relatively young as a standalone company, has maintained its dividend growth inherited from Abbott, positioning itself as a Dividend King. The acquisition of Apogee Therapeutics for $10.9 billion is a strategic move to bolster its drug pipeline, particularly with d", "url": "https://finance.yahoo.com/healthcare/articles/abbvie-already-dividend-king-heres-003500796.html", "source_name": "Market source", "published_at": "2026-07-12T23:06:57", "published_display": "12 Jul 2026 23:06", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie stock holds steady after a new U.S. market backdrop", "summary": "AbbVie Inc. (US00287Y1091) remains a significant U.S. healthcare company, focusing on its diversified drug portfolio with strong exposure to immunology and aesthetics. The stock's stability is attributed to its broad therapeutic franchise, multiple revenue streams, and establishe", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/abbvie-stock-holds-steady-after-a-new-u-s-market-backdrop/69751563", "source_name": "ad-hoc-news.de", "published_at": "2026-07-12T07:24:59", "published_display": "12 Jul 2026 07:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Sco", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPV1JxaU9DM3NydWo0bVBvaDF1QTczSFFWYmpqN0JXLTduZ04xdmxYWTRaeEtHYTdvVkNwSlNNM0JwZHM4a3RFTGI5OXFhajlwUW1IaXpCTXM3X2Nwak9sbjdCQ1lCM2ttZ2l6X3dGa3VvNWJmM0x5Zzllc1F4UWI2MnJJYjVhNUJ1V2k4ZnpFNTVhMzJlVG4tTm5ITTNiWjRKQmh0QTdDQ2lHSDYwOGc2cC1FUDhNaHM?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-11T00:36:20+00:00", "published_display": "11 Jul 2026 00:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABBV News | ABBVIE INC (NYSE:ABBV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE1XdjVhb0wxSW1QVDRGeGVKYkhDbDhycUpxa1JITjVJZjFfWEdOalprT2VxbnBteEpnNEZNcE5BYXM0dFktVkNQTGQyeXRvRy1zU05iSnk5OENxeUk?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:04:00+00:00", "published_display": "11 Jul 2026 00:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPTGRXdGVwTTByVUs5T0UtSXlZMW9oTmd4dlFITi00LTF4ZkkwMi1GSTZXV2RZdU1VRFJnLThHRDgzZ2R5dTZaWERhVmtJaEdXVkZCN1cxREVydmM5WldNMzlYSU16cnlpcjltOFVDdTBkelphM3lyMDFpRlI1eEpZbW5pbmhVYV96Ui0xRnRQUmFqR0pKaDJBUGR2NDM?oc=5", "source_name": "Market source", "published_at": "2026-07-09T21:45:04+00:00", "published_display": "09 Jul 2026 21:45", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Wins EU Approval For Tepkinly, Is The Stock Fully Valued?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T18:55:36+00:00", "published_display": "08 Jul 2026 18:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock Trades At A Discount To Fair Value", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNbFZuVGhLck5kN2RTbnlyY05IVE1qMTB1cDFNX0JQcm5sUlRkUWRiRjRLaENRSG15OGdkbnY0ZEkxTndVVFEzdUNBUFJPZktCd2pJZk5GTVB2SHZaaHNLbG1oU2YxMm5hRlB6dE1kS2dVTkE5RzFOeXpaZk51RUVVQlV2Wnh1ZmpacFB2WGNfMkI1VnVUUGhnMENZd0cwQWtqMjRKMFJXMEtabl9GSTZJWXljalJ5ektIdmRJcw?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQblhVZzlvSk1rVU1xcDdOOWlmSUlVSFVhOVY4WXNYTjJyX0NNUFM1Z01Wb1JPaTNnWG1IQkRiRmdfLTJnbUJSX2ZQQ3BSaUd3RllENi1GT2JMSU5sNTN2T3hHS1o4ZkVTblFsbVBGVFA2VWJXRVFuSmRHSnplUEJ5VnVfSzhqb0lXTEhzajhET2RQMWd5MXVoN1UzZktmYnEzeGc?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AbbVie (ABBV) Fully Valued After New Rinvoq And Skyrizi Approvals?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Stock Rockets 17% With 5-Day Winning Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQWlNibHR4Y093endvUXE1REJKYjRkM0RSZ1N1QjJZMl9SMllNVEtBQWJmaHpzQktlMHhEOHh1UU5MQ1ppR3BLLUxlZ1lsUjA2ZDZGZVBhdDQyU0YxWHFTYldBZnRCY1NQQmsxUHFQbjZ2Vkk5UzZtdmtNNmlmRXgzbXNSbVdkY1BpSlBjZGFrRzEyeERMT1ZDVlEzWGhqbDk4cXRQSkxWZDVzZVZsMlRz?oc=5", "source_name": "Trefis", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock After 1-Year 41% Rally And Apogee Deal Valuation Check", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOeC16WWxHNnNDakNqX21pTWdHb0ZpUktlejEyRDQyU3RwNGVkSjk1NTA1SUt2QmxTNmtVSUdiS1hxNlVEYnJCUGlvR0UydnpTcGdMSkY1aHBLNDNmOVYySWxKeUotUndkeG5pM3BIUnpHVmpPbXR5bU1GRG9Pdm1KdGNZSlluWjZ4SktFLTBQZ3c?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNMl9fd1RVMWhLQW9KUU5jRzBWU0F2QmNpbEFWVXFGRk9WQ01HYXUyYmNOVEdQVW12WlZ0RnJ6Z2UyUHJYb3lyYU00RHpEVmZNdC01dEdsakhvWHhrZ2lVSkxISVNNZWJBN0hEZW8zblMxWC1UYVR3Ylg1QWwwYlJCSUN3a0tFaEdlcThFSGpUNmJvakNW?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Stock Leads 3 Cash Flow Picks Trading Below Estimated Value", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock Draws Fresh Price Target Split After Apogee Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOTThub0wyWHVFUFV0Xy1Vck8yOWhxQkdSTlI1M09Jdm1KRzM3ZkFVZ0pQV2MyR0FEemxuZTNfaENJaFpaRmpIdDB6czZHWS1XbTdPSG9BclVxUHFRVDV3SlNoTjRfUnhXNFpxeW5NS181bXNpdXhtQjhtR1lqSVh4bkJIMkFIM0JURFRSTElfZjBrUU1rVmd5aDB3?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie to Acquire Apogee Therapeutics in $10 Billion Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOVVZRdFFhZEtER3ZMRHhJZG02MGpYb0V2cVBuWXdXdUx2bllQMTZtRVBqMENycnhYYVpnUTVOM3hpMHBzZTUxXzMydDYtZlFSSEIyN0pDUEE4SWVhUTZNekM2V0dEWnRfWl8welh5Sk1oSDNuMDJQVzEteGNSclJkOXZaaXVudHZL?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPVFVxY01QUEhnc01sTHFMdnpPVndYWjk5Y01BR29tS1NZLXhyT2ZpelFIcDc0Ql9vRnAwM0pfeW5LMFkzYzNhenpEMTk5UzJjX1pFWmZVOG9iX1dmcXNoY2F6NGZBa0l2Y1NtNXBjMllnZjVxZ3hYeWdLNThienFDSWVqZGlKQnR1S0NObE9MaDRGYjJZempWTGJ6NkdScWZ4SkhSVllMenNmSGh0ckI2bERDSExJUTFCM1Z1Z2pIN1RGS0lkSi1sWXF5TXl3UllyaEhBNVAtNmI?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why AbbVie Stock Jumped Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQQmpBaVhzV2Nyd3hmdmRuQVpJUjhnbXpOajdCdlpVZ3p3LXBkVlAza0VTWkhKeW1jSzc2YmpnUUpUVG1ocjduNlZyQ1dyYTdQdTVNT1AzNUlDWHNBV3dXYkN4Ti02RTk5ZTJlN29NWTFwTG15cHk2UDcyZlM3Y1ltWTNJeVliemYwdlg1d1liNzFUZE5sTlRRaFZn?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNNVdQUG5hMEZpMWh2eHIzNkUtZ2VGajJNX2ltcFF1TmRyQUxDckNCMThudHBKNWlTbHRlb28zQko4MFZaVWRnelFQeGdrM2pnN2Nya0hiS1F3NlA3bXVMeVlFYm1URXJIVVcybnhaYjJUZm1YOTd1b2llcHRKc1pYZ1lKeWZvbVFEbEZpZWNQZWJmbjR1RWtyTm5pdw?oc=5", "source_name": "Market source", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock Weighs DCF Upside Against Elevated P/E At US$227.73", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQZmFkN0p6MUh6T3BVZXY4OFB6YVJEeE1lYXl0X3ZBUUxuczI4TFgzWTBkaDB2MkNPaWtheVdwYWl2SVctSzNrbXk5dFgtMjk2UlVGLWl0UmFZQXFXQmdkUUlGdXRKRVRoczJZZUZWR1ZvRVZpNVQyNU91d25GeUxFXzJoYjV3VFQ4WExxVE9jbXhTYWhmcXFpWA?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AbbVie Inc. (ABBV) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPWDJhb3N0MVdzcUtTTDU5YlI0MGZEdEJMZmszU01TYmpNMFJiUE5uRHJEZVVqak1tbUphNDFLb0lPdzJDM1BzSnZzU2tSd2lNRk1LZFBoY3Q5Z3hXT2lJeWo0X1pYd29xeWRsYjBGTlY4em1LTGcyV2xheF9reFh2VkhpbnplcVhQbzBhUldENlUzYmdUQ0E?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOaC02SmUycjdKa0ZLTS02c0pXblZ2d0xtWVNpZDZPdnNNbU1Pc1pOdWZQbWtwcjNsTmVZSzg1UEw3UElXUjNlYlNmUF9zdVA4NHNHNHZ5ZVNkYVFhSUxua0VNVjZndzA5alFkeUhDWUJkaWJlSXp2d3pGMlkxUkg4VzlqRVBQR2poR2pueEo5NA?oc=5", "source_name": "Market source", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie (ABBV) Stock Trades Up, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPbjNSdm0tWjU0bWtUazdaamZFRFZjOXFrekRzQ1BnTnAyQXJkaW4xTE94UU5hWkdqV002LVpSLUJSSlNQd0xzS3B4REppX2psVjlkTVIyeC1vUm5IbTZPalU0MFJUMG5HSG85RzRHZ1ZjOGgxaElLVXU5OTYxVl9KQ3JCNWJ1eHFUMzJ6Y2h1aW1UVnRNbjloMVBtUEtZcm9w?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Invests $1.4 Billion into New Manufacturing Campus in North Carolina", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxONEFDQV9qWDEtcEtUNHlnYXpHQUYyWUJCTHVhWVJwS204LTNkNlJTVGw1cWU5R0d6R0dYcWlmNmJydzlzNTdoRG14bWhMOW9IWUpCQk1XWWxlUnBoX0VvdXk3YmhkTXJMQzRGeVZQdXd2SFVSVGhlTG9yRUNieFhIbFhPSDRGWUFUVlBuLUdyRkFoRzg2bWVRMHB4WjVUdG8?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPa3FhWENLaVV5TFhFX0ZNQmgtSEZncFJBRjlsUURGT0hKX2tpNGZURURWMjdDOUZ1MWJWUlRHeXRjU2NFRWZkc0ZpalRGUElyRHpKeEZGZmxfQkdEOEdUMTZpcHQxRy1QelVoOXBieEVNWDJibHdteHJYbWFjWHUzUlZ0ZVBsdkM2WGczbFFsbDNnbUVnYmNuQlRRZS0zbU1PYTZWZjZ0MVBtSmlXUFlTQzZDU2RhV1ZzZGc?oc=5", "source_name": "TradingView", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Haisco Enters $745 Million Exclusive License Agreement with AbbVie", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxORGtNdlV6OWh2aWRHeTFiWnFFdGp5a3JSNTBvWW43RlFtS2o1UWYwN2g3LXVuRmlCVGstdWU1ZThHVnJPSUE5RkVyTmVPd2sxeW5HMHMzc0lYUndpU1lYbnhMRGtqVkVoeS1tNzhDOUdicV9QZF9obFhfeGJVb0JrMEc4TmJzb2JUR1VYT1V0dk0yZjJPVEE?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxPZmJKQ3l2S2FkYjlsd0xiQWUwX1V5d3R2cEMzblBrVmNTUEdtdWFndkl6UnAyOTVQYW96VGdiQzlaX3dwQ0FjSUNHVE9mSy1kLTlhX29HUmFfcG55ZlRRV2lfcGl2S2l5ZXc0TUZwcmFxRGFHVjJyWW9EMXk4UVFWRUxQMEZybElFTll6NjNsNUxKcUJ6cEE2aTZPYXpMYXhYRm51LTRlRHp2RXIzQjFfSG1Wc3pVcFkyRVZaUjduTjFOWlZ5TmV1Q1VKWUdPREtlbW5sX3c3MkltOWVXRWlHMEdUSnBBTllFRjQ3bFkwSndnc2FiZFlkOHhB?oc=5", "source_name": "StockStory", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharma Manufacturing Roundup: AbbVie Invests $380 Million to Expand API Manufacturing, Bora Pharmaceuticals and GSK Enters Five Year Manufacturing Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOT2NTdUZpUFVNcEFaeUoyV2JnNVNRVVhxS2NkajNVTjJWQk5HOGdhblBsdjhHNXFsbEZucXVkRmdqTTByVUVXdURjcERLSEM2bWJ5aEV4NkRQRlBHYWVBT0loT2VTSkM2MElLbTR2aWNYd2J3TkFlUDVLQkhBLVJ1dGN3Zkp5cWtDWnRqRGlNeUc4ejlhMVoza0JUZlE3VGp0bkc4YTNLei1DVjhkQXYtaTVYeGlHbEF2ZGtMd1ZFWmpWUGtZUE5iSkdTQ2hkeHF5RUlVRl80UU5fOU1KdGFkZVItSXZXaV9YVXFv?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie\u2019s $380M Illinois build to add 300 jobs, boost obesity drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPV3BsWk1QcVJ4Z3BOdnVvenAwdWFFdzBBTnVWZHZyaF9xelR2dzAyMFVlb0w3c2NfMVowZFFpQXczUktPQ1lMNHdvaUNSUWFKb0Y3Umw0RkdXZWVmZkhzZjhDMDYyNmI3S1RsQmFacmVzMEJWcl9aN3hHQUxRbk9KdWJpd2J2ZF9MMkgtVGVaQm1na3V5bmpLTm5YYnh3b2pFSXlnbGMxT295WFBnX3B5bFU2OGxIaHBEZ1BN?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Joins Trump Drug Pricing Effort, Pledges $100B in US R&D Investment", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNZmdzdGFBWHdqeU9OQzB1ZkZwWUczbTN1cS1vTWJWYjZVaHVPY0F3d1V4ZHhGb0dRQ2x0WnFSUUxpWGtISGx3ZmZ4WmpvakZydS1LYTZaeUdzbFZFRHFuMWFtZ1dkemQyTEw4NlFIUG1CWV81bGpfcndlZ3g2OUhMRElZLWRNc1piUVFRWHNLV0ExdU9jWjI5Yl93c3Zfb1U?oc=5", "source_name": "The American Journal of Managed Care\u00ae (AJMC\u00ae)", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 108, "total_relevant": 46, "sentiment_summary": {"positive": 15, "negative": 2, "neutral": 29, "score": 55, "total": 46, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 15.2, "count": 27}, {"event": "deals", "label": "Deals and strategy", "weight": 3.3, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "earnings", "label": "Earnings", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 248.08, "latest_week": "2026-07-10", "one_week_move": -5.0, "four_week_move": 8.9, "twelve_week_move": 19.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.119599, "market_dynamics_buy_signal": false, "relative_strength": 2.836438, "fair_value_gap": 36.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.224, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.0% over one week, +8.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "simplywall.st", "count": 4}, {"label": "Pharmaceutical Executive", "count": 4}, {"label": "TradingView", "count": 3}, {"label": "The Globe and Mail", "count": 2}, {"label": "Stock Titan", "count": 2}, {"label": "GuruFocus", "count": 2}, {"label": "marketscreener.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Deals and strategy", "count": 6}, {"label": "Analyst action", "count": 5}, {"label": "Earnings", "count": 3}, {"label": "Guidance", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-5.0% over one week, +8.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?"}], "updated_at": "2026-07-16T08:13:15.554232+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}